A detailed history of Marathon Capital Management transactions in Astrazeneca PLC stock. As of the latest transaction made, Marathon Capital Management holds 168,090 shares of AZN stock, worth $13 Million. This represents 2.84% of its overall portfolio holdings.

Number of Shares
168,090
Previous 163,010 3.12%
Holding current value
$13 Million
Previous $12.7 Million 13.29%
% of portfolio
2.84%
Previous 3.19%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$63.2 - $79.58 $321,056 - $404,266
5,080 Added 3.12%
168,090 $11 Million
Q3 2024

Nov 14, 2024

BUY
$76.67 - $87.62 $87,250 - $99,711
1,138 Added 0.7%
163,010 $12.7 Million
Q2 2024

Aug 14, 2024

SELL
$66.81 - $80.83 $14,364 - $17,378
-215 Reduced 0.13%
161,872 $12.6 Million
Q1 2024

May 15, 2024

BUY
$61.03 - $69.57 $4.08 Million - $4.65 Million
66,897 Added 70.28%
162,087 $11 Million
Q4 2023

Feb 08, 2024

BUY
$61.89 - $69.28 $5.89 Million - $6.59 Million
95,190 New
95,190 $6.41 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $239B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Marathon Capital Management Portfolio

Follow Marathon Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marathon Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Marathon Capital Management with notifications on news.